Coronavirus: strain causing severe diarrhea and vomiting in pigs ‘could be spread to humans’



[ad_1]

A strain of coronavirus that has been infecting pigs in China since 2016, causing severe diarrhea and vomiting, could spread to humans, a study warned.

The strain, ‘swine acute diarrhea syndrome coronavirus,’ or SADS-CoV, is believed to have come from bats and has been worrying the livestock industry.

It is more dangerous for the piglets. A broader outbreak of SADS-CoV could cause serious economic damage in those countries that depend on the production and sale of pork.

The United States, for example, was the world’s third-largest producer of pork last year, and the industry was previously hit by another swine coronavirus in 2012.

Researchers from North Carolina have shown that SADS-CoV can become infected and replicate within human airways, liver, and intestinal cells.

A strain of coronavirus that has been infecting pigs in China since 2016, causing diarrhea and vomiting, can spread to humans.  In the photo, a pig on a Chinese farm (file image)

A strain of coronavirus that has been infecting pigs in China since 2016, causing diarrhea and vomiting, can spread to humans. In the photo, a pig on a Chinese farm (file image)

SADS-CoV belongs to the same family of viruses as SARS-CoV-2, the agent behind the COVID-19 pandemic, but it belongs to a different genus. Specifically, SADS-CoV is an ‘alphacoronavirus’, while SARS-CoV-2 is a ‘betacoronavirus’.

“Many researchers are focused on the emerging potential of beta-coronaviruses such as SARS and MERS,” explained paper author and epidemiologist Ralph Baric of the University of North Carolina at Chapel Hill.

“In reality, alphacoronaviruses may be just as important, if not greater, human health concerns, given their potential to jump rapidly between species.”

The researchers also explained that SADS-CoV is distinct from two alphacoronaviruses of the common cold in humans, HCoV-229E and HCoV-NL63.

In their study, Professor Baric and his colleagues investigated the risk of the so-called “spillover” – that SADS-CoV could jump out of pigs and infect human populations.

To do this, they infected various types of synthetic cells with the porcine coronavirus and monitored how the virus replicated and spread.

The researchers found that a wide range of mammalian cells, including primary human intestinal and lung cells, are susceptible to SADS-CoV infection.

However, unlike SARS-CoV-2, the team noted that the porcine coronavirus is capable of replicating faster in intestinal cells, rather than in the lungs.

Furthermore, the findings suggest that, when it comes to SADS-CoV, humans have not acquired the herd cross-protective immunity that may prevent us from contracting coronaviruses from animal populations.

“SADS-CoV is derived from the bat coronaviruses called HKU2, which is a heterogeneous group of viruses with worldwide distribution,” said article author and public health expert Caitlin Edwards, also from the University of North Carolina.

“It is impossible to predict whether this virus, or a closely related HKU2 bat strain, could emerge and infect human populations,” he added.

“However, the wide host range of SADS-CoV, along with the ability to replicate in primary lung and human enteric cells, demonstrates a potential risk of future emergency events in human and animal populations.”

“The promising data with remdesivir provide a potential treatment option in the event of a human overflow event,” said Ms. Edwards. We recommend that both pig workers and the pig population be continuously monitored for signs of SADS-CoV infections to prevent outbreaks and massive economic losses, ” said Ms. Edwards

The researchers also explored the potential against the swine coronavirus of the broad-spectrum antiviral remdesivir, which has been touted as a treatment to speed recovery from COVID-19, and was recently administered to US President Donald Trump.

The team’s preliminary results hint that the drug is effective against SADS-CoV, although tests in animals and other cell types will be needed to confirm this.

“The promising data with remdesivir provides a potential treatment option in the event of a human spillover event,” said Ms. Edwards.

“We recommend that both the pig workers and the pig population be continuously monitored for signs of SADS-CoV infections to prevent outbreaks and massive economic losses.”

“It is not surprising that we are currently looking for partners to investigate the potential of SADS-CoV vaccine candidates to protect pigs,” said Professor Baric.

“While surveillance and early separation of infected piglets from sows provide the opportunity to mitigate larger outbreaks and the potential for contagion to humans, vaccines can be key to limiting global spread and human emergency events. “.

The full study findings were published in the journal Proceedings of the National Academy of Sciences.

REMDESIVE: KEY FACTS

Remdesivir, an antiviral drug first developed to treat Ebola, has been used experimentally in COVID-19 patients since the early days of the outbreak.

The FDA issued an emergency use authorization for the drug on May 1, in response to preliminary results from a notable study that was published in late April.

According to Hackensack Meridian Health, initially only seriously ill hospitalized COVID-19 patients were eligible to be treated with remdesivir, also known as Veklury.

On August 28, the FDA extended its clearance to all hospitalized adult and pediatric patients with suspected or laboratory confirmed COVID-19, regardless of the severity of the illness.

“The FDA continues to make safe and potentially helpful treatments for COVID-19 available as soon as possible to help patients. The data supporting today’s action is encouraging. The data shows that this treatment has the potential to help more hospitalized patients suffering from the effects of this devastating virus, ‘said FDA Commissioner Stephen M. Hahn, MD.

“We are working with drug developers to conduct randomized clinical trials to further study the safety and efficacy of a number of potential therapies for COVID-19.”

However, in August, a report from California-based drug maker Gilead Sciences Inc found that the drug’s effects can only be seen in people with severe infections.

There are claims of miraculous recovery, better chances of survival, and shorter illness, but other studies have found that it makes no difference for hospitalized Covid-19 patients.

Remdesivir produced encouraging results earlier this year when it showed promise in both preventing and treating MERS, another coronavirus, in macaque monkeys.

The drug appears to help stop the replication of viruses like coronavirus and Ebola alike.

It’s not entirely clear how the drug accomplishes this feat, but it appears to prevent the virus’s genetic material, RNA, from being able to copy itself.

That, in turn, prevents the virus from proliferating further within the patient’s body.

[ad_2]